Daprodustat

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 150 publications

Daprodustat augments red cell and γ-globin production in models of sickle cell disease.

Daprodustat augments red cell and γ-globin production in models of sickle cell disease.

Journal: Blood. Red cells & iron

Published: June 10, 2026

LC-PDA & LC-MS/MS approach of Daprodustat: forced degradation study.

LC-PDA & LC-MS/MS approach of Daprodustat: forced degradation study.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: June 05, 2026

Hypoxia inducible factors regulate pneumovirus replication by enhancing innate immune sensing.

Hypoxia inducible factors regulate pneumovirus replication by enhancing innate immune sensing.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 07, 2026

Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.

Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.

Journal: Renal failure

Published: February 03, 2026

Association of nutritional indices with hyporesponsiveness to hypoxia-inducible factor-prolyl hydroxylase inhibitors in patients with chronic kidney disease: a single-center retrospective observational study.

Association of nutritional indices with hyporesponsiveness to hypoxia-inducible factor-prolyl hydroxylase inhibitors in patients with chronic kidney disease: a single-center retrospective observational study.

Journal: BMC nephrology

Published: January 15, 2026

Prolyl hydroxylase inhibitors, roxadustat and daprodustat, inhibit platelet activation and thrombosis through the PI3K/AKT/HIF-1α pathway.

Prolyl hydroxylase inhibitors, roxadustat and daprodustat, inhibit platelet activation and thrombosis through the PI3K/AKT/HIF-1α pathway.

Journal: Biochemical pharmacology

Published: November 29, 2025

Daprodustat in heart failure and renal anemia: Still early, but promising.

Daprodustat in heart failure and renal anemia: Still early, but promising.

Journal: Journal of cardiology

Published: October 13, 2025

Structure-Based Optimization of HIF-2α Agonists That Synergistically Enhance Erythropoietin Production with PHD Inhibitors.

Structure-Based Optimization of HIF-2α Agonists That Synergistically Enhance Erythropoietin Production with PHD Inhibitors.

Journal: Journal of medicinal chemistry

Published: October 06, 2025

Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature.

Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature.

Journal: Cureus

Published: September 29, 2025

Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan.

Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan.

Journal: Current medical research and opinion

Published: September 19, 2025

In Vitro and Ex Vivo evidence that pharmacological induction of the hypoxia response pathway efficiently restricts measles and Nipah virus infections.

In Vitro and Ex Vivo evidence that pharmacological induction of the hypoxia response pathway efficiently restricts measles and Nipah virus infections.

Journal: Emerging microbes & infections

Published: September 17, 2025

Effects of Daprodustat on Iron Metabolism in Peritoneal Dialysis Patients: An Exploratory Study.

Effects of Daprodustat on Iron Metabolism in Peritoneal Dialysis Patients: An Exploratory Study.

Journal: Blood purification

Published: August 11, 2025

Showing 1-12 of 150

Last Updated: 06/30/2026